key: cord-0070756-vbkusfch authors: Guo, Clara Z.; D'Onofrio, Gail; Fiellin, David A.; Edelman, E. Jennifer; Hawk, Kathryn; Herring, Andrew; McCormack, Ryan; Perrone, Jeanmarie; Cowan, Ethan title: Emergency department‐initiated buprenorphine protocols: A national evaluation date: 2021-11-29 journal: J Am Coll Emerg Physicians Open DOI: 10.1002/emp2.12606 sha: b8de4ce67208cfef762380b83c98f55a0d9925d3 doc_id: 70756 cord_uid: vbkusfch OBJECTIVE: Emergency department‐initiated buprenorphine (BUP) for opioid use disorder is an evidence‐based practice, but limited data exist on BUP initiation practices in real‐world settings. We sought to characterize protocols for BUP initiation among a geographically diverse sample of emergency departments (EDs). METHODS: In December 2020, we reviewed prestudy clinical BUP initiation protocols from all EDs participating in CTN0099 Emergency Department‐INitiated bupreNOrphine VAlidaTION (ED‐INNOVATION). We abstracted information on processes for identification of treatment‐eligible patients, BUP administration, and discharge care. RESULTS: All participating ED‐INNOVATION sites across 22 states submitted protocols; 31 protocols were analyzed. Identification of treatment‐eligible patients: Most EDs 22 (71%) relied on clinician judgment to determine appropriateness of BUP treatment with only 7 (23%) requiring decision support tools or diagnosis checklists. Before BUP initiation, 27 (87%) protocols required a documented Clinical Opiate Withdrawal Scale (COWS) score; 4 (13%) required a clinical diagnosis of withdrawal with optional COWS score. Twenty‐seven (87%) recommended a minimum COWS score of 8 for ED‐initiated BUP. BUP administration: Initial BUP dose ranged from 2–16 mg (mode = 4). For continued withdrawal symptoms, 27 (87%) protocols recommended an interval of 30–60 minutes between first and second BUP dose. Total BUP dose in the ED ranged from 8 to 32 mg. Discharge care: Twenty‐eight (90%) protocols recommended a BUP prescription (mode 16 mg daily) at discharge. Naloxone prescription and/or provision was suggested in 23 (74%) protocols. CONCLUSIONS: In this geographically diverse sample of EDs, protocols for ED‐initiated BUP differed between sites. Future work should evaluate the association between this variation and patient outcomes. From 1999 to 2018, the opioid epidemic claimed over 446,000 lives in the United States. 1 In 2020, there was a 21% increase in fatal overdoses, two thirds of which were opioid related. 2 Medications for opioid use disorder (MOUD), particularly methadone and buprenorphine, reduce mortality, increase treatment retention, decrease opioid misuse, and reduce craving and withdrawal. [3] [4] [5] Despite benefit, the majority of patients with opioid use disorder (OUD) do not receive MOUD. [6] [7] [8] The emergency department (ED) is an important setting to identify patients with OUD and initiate buprenorphine (BUP). 6,9,10 From 2005 to 2014, opioid-related visits in the United States to EDs doubled. 11 In 2015, a randomized controlled trial demonstrated that ED-initiated BUP increased engagement in treatment at 30 days, reduced opioid misuse, and was cost effective compared to brief intervention with a referral or referral alone. 10, 12 Although there has been a modest increase in ED BUP prescribing, few ED clinicians indicate high readiness to initiate BUP. 13, 14 When experience is lacking, clinical protocols may help facilitate adoption of ED-initiated BUP. [14] [15] [16] Most research on BUP has not been conducted in EDs, and existing protocols for BUP initiation in other settings may not reflect the unique needs of the ED and/or its patient population. The recently released guideline published by the Substance Abuse and Mental Health Services Administration (SAMHSA) on EDinitiated BUP suggests dosing that is lower and less frequent than the emergency medicine literature. [17] [18] [19] [20] [21] [22] [23] Instead, the SAMHSA guideline mirrors dosing regimens from clinical trials and observational studies in office-based settings. 3, 24, 25 Although patients presenting for office-based BUP initiation are not physiologically different from those in the ED, context matters. For example, often the individuals with OUD who use the ED represent vulnerable populations, lacking other sources of healthcare access. They are more often uninsured or underinsured, and many have coexisting mental health issues and unstable housing. 17 The generation of site-specific evidence-based protocols may be an important strategy to streamline implementation and enhance the adoption of ED-initiated BUP. 14 Understanding variations and similarities in BUP initiation protocols across a diverse sample of EDs can help guide recommendations for protocol development and future research on best practices. We sought to characterize a national sample of ED-initiated BUP clinical protocols on (1) identification of treatment-eligible patients, (2) ED BUP administration, and (3) discharge care with the goals of providing recommendations for key components of an ED-initiated BUP protocol based on similarities across protocols analyzed, as well as lay the groundwork for research to evaluate best practices. NCT04225598). 28 The ED-INNOVATION protocol has been published elsewhere. 28 Briefly, the study has 2 components: (1) an implementation phase using implementation facilitation to enhance adoption of ED-initiated BUP and (2) a randomized controlled trial comparing the effectiveness of 2 BUP formulations, sublingual (SL-BUP) and a 7-day extended-release injectable (CAM2038, XR-BUP) among patients with OUD on the primary outcome of engagement in formal addiction treatment at 7 days. 28, 29 As part of the implementation facilitation phase but before initiation of any associated support efforts, all sites were required to submit their clinical BUP initiation protocols for review by the lead research team before October 31, 2020. Two investigators independently reviewed all submitted clinical BUP protocols using a standardized data abstraction survey created in This study demonstrates that variability exists across emergency department-initiated buprenorphine protocols across a sample of 31 geographically diverse sites; however, most protocols used a similar framework of identifying eligible patients, further assessing eligibility, providing buprenorphine, and discharging patients with harm reduction and referral to care. Future research could best test and define the specific steps within that framework. This study is descriptive with no formal hypothesis being tested. Descriptive measures used to describe the data include frequencies and percentages for nominal and ordinal categorical variables and mean, mode, minimum, maximum, and total range where appropriate for continuous variables. Interrater reliability after initial data abstraction was calculated for categorical and ordinal variables using either unweighted or weighted Cohen's kappa, respectively. All sites (n = 33) EDs participating in ED-INNOVATION submitted protocols for lead team review. Among the 4 new sites added to the study, 2 were from the same health system, had the same study staff, and used the same protocol as their original sites. Therefore, 31 protocols were analyzed, representing EDs from 22 states ( Figure 1 ) and a variety of practice settings. Two sites had previously participated in a clinical trial with the lead research team on ED-initiated BUP (CTN-0069, NCT03023930), during which feedback was provided on their ED-initiated BUP protocols. 29 The lead research team, as an ED participating in clinical trial enrollment, also submitted a clinical protocol for review. The remaining 28 sites submitted protocols with no prior lead team feedback, although all had access to the lead team's protocol for reference. Six (19%) protocols had guidelines for universal screening for substance use disorders; 2 (6%) recommended using chief complaints or triage screening and 4 (31%) used either a site-specific assessment or other screening tools such as the NIDA Quick Screen or Screening and Brief Intervention and Referral to Treatment screening tool. 32, 33 ( Table 1) . Twenty-one (68%) protocols mentioned ancillary staff involvement, including 12 (39%) that used social workers, 11 (35%) that used peer counselors/advocates, and 7 (23%) that used care managers. Twenty-eight (90%) protocols specified using SL-BUP in the ED; among those, 3 (10%) also suggested the use of intramuscular or intravenous routes of administration in certain circumstances. The remaining 3 (10%) protocols did not specify the mode of BUP administration. Fifteen (48%) protocols specified using the buprenorphine/naloxone combination product; among those, 6 (19%) additionally allowed buprenorphine monotherapy use. The remaining 16 (52%) protocols did not specify formulation. (Table 2) . The maximum total BUP dose in the ED was specified in 29 (94%) protocols and ranged from 8 mg to 32 mg (mode 16 mg). In terms of worsening or perceived precipitated withdrawal, 9 (29%) protocols described ancillary medications for continued withdrawal symptoms. The most frequently listed medications were ondansetron, loperamide, clonidine and nonsteroid anti-inflammatory drugs. Ten (32%) protocols included specific guidelines for precipitated withdrawal; among those, 5 (16%) recommended additional BUP for precipitated withdrawal, and 5 (16%) recommended ancillary medications without additional BUP. Treatment for patients presenting with low COWS scores varied. Twenty-two (71%) protocols included recommendations for management of patients with low COWS scores. Among those, 12 (39%) recommended discharging the patient from the ED with a prescription for Number of sites with guidelines related to discharge care instructions: (a) policy for low COWS score, (b) provision of home BUP induction instructions, (c) BUP prescription at discharge (note that some site protocols allowed several dosages to be prescribed at discharge), (d) naloxone for overdose prevention, and (e) harm reduction education. home initiation of BUP; 7 (23%) provided the option of either discharging or holding in the ED; and 3 (10%) recommended holding the patient in the ED until withdrawal worsened. (Table 3 ). Referral to outpatient treatment was addressed by all but one (97%) protocol, although only 2 (6%) explicitly mentioned a warm handoff. A BUP prescription provided at discharge was recommended by most, 28 (90%), ranging from 4-32 mg daily; the remaining 3 (10%) protocols did not include information on a discharge prescription of BUP. When prescribed, the most frequent dose (mode) of BUP was 16 mg daily (recom- protocols. Other specific harm reduction education, such as explicit overdose education, was mentioned in only 5 (16%) protocols. Kappa values for categorical and ordinal survey questions ranged from 0.37 to 1.0. Only 1 out of 40 survey question had a kappa value <0.41 and only 5 had a kappa <0.61. In general, observers agreed on data abstraction conclusions; agreement between observers was moderate to near perfect. Only 3 disagreements between the data abstractors could not be resolved and required adjudication by a third reviewer. Our findings may be subject to selection bias. Although the ED- Finally, the protocols themselves may not accurately reflect clinical practice, but prior qualitative research suggests that clinicians less experienced at BUP initiation would likely lean heavily on protocols if they existed and that the absence of protocols is a major barrier to adoption of ED-initiated BUP. 14 Our study demonstrated considerable variability in protocols related to all 3 steps of ED-initiated BUP: (1) identification of treatmenteligible patients, (2) BUP administration, and (3) discharge care. In most protocols, clinical judgment rather than formal diagnostic Overall, protocols varied in their listed contraindications to ED-initiated BUP. The most common contraindication was recent methadone use, likely due to the risk of BUP-precipitated withdrawal. 3, 24 Other listed contraindications, such as alcohol and/or benzodiazepine withdrawal or use, may be viewed as complicating factors of withdrawal or a misunderstanding of risk. 36 Although SAMHSA listed BUP allergy as its only contraindication, only 4 sites did so in their protocols. 24 Pregnancy was not a contraindication to ED-initiated BUP in any protocol; however, pregnancy was mentioned in most protocols as a special consideration or as a required lab test before initiation, likely because of prior recommendations to use BUP monotherapy in pregnancy to avoid prenatal exposure to naloxone and to provide appropriate, rapid follow-up. 37 ED literature has also shown that higher doses of BUP (>12 mg during an ED visit) in patients experiencing opioid withdrawal can be tolerated in select patients. 27, 38, 39 Although the lower limit of the COWS for ED initiation differed between protocols, ranging from 5 to 12, most (61%) recommended unobserved (home) initiation for those not in adequate withdrawal for ED BUP initiation. Unobserved BUP initiation has several advantages. 40 It is less resource intensive, requires shorter ED lengths of stay, and adds individual patient flexibility as to how and when to start treatment. 40 In summary, the ED is a unique setting in which to treat patients with OUD. In fact, some have argued that withholding care for those with substance use disorders in the ED is a violation of federal law. 55 Our study aimed to describe the landscape of ED-initiated BUP protocols in a geographically diverse sample of EDs in the United States. Protocols differed regarding identification of treatment-eligible patients, ED BUP administration, and discharge care, demonstrating both the flexibility of BUP initiation in the ED setting and the realities of carving out a lifesaving strategy with little previous guidance. Although variation existed across the 31 protocols, most used a similar flow of patients from ED presentation to discharge. We therefore recommend the following evidence-based framework (Figure 2 and harm reduction strategies affect patient outcomes and support dissemination of ED-BUP initiation practices to continue to drive innovation that improves patient outcomes. Identification of treatment-eligible patients a. Inclusion criteria that must be met before ED BUP administration: OUD determination, active withdrawal, and time since last opioid use b. Minimum COWS value before ED BUP initiation c. Absolute contraindications to ED BUP d. Other required evaluations (pregnancy determination, other labs) e. Screening guidelines for patient identification f. f) Involvement of ancillary staff, such as social work, care managers, and peer counselors, for patient identification and/or care coordination Drug and opioidinvolved overdose deaths -United States Provisional drug overdose death counts. National Center for Health Statistics The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update FAQs: Provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies The adverse impact of COVID-19 on individuals with OUD s the urgent need for reform to leverage emergency department-based treatment. NEJM Catalyst Medication-assisted therapies-tackling the opioid-overdose epidemic Trends in buprenorphine treatment in the United States Emergency departmentsa 24/7/365 option for combating the opioid crisis Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial Patient characteristics of opioid-related inpatient stays and emergency department visits nationally and by state, 2014: statistical brief# 224. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Addiction Trends in the use of buprenorphine in US emergency departments Barriers and facilitators to clinician readiness to provide emergency department-initiated buprenorphine Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey Emergency department clinicians' attitudes toward opioid use disorder and emergency departmentinitiated buprenorphine treatment: a mixed-methods study Substance Abuse and Mental Health Services Administration: Use of Medication-Assisted Treatment in Emergency Departments. HHS Publication No. PEP21-PL-Guide-5 National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration Buprenorphine (BUP) hospital quick start Computerized clinical decision support system for emergency department-initiated buprenorphine for opioid use disorder: user-centered design Buprenorphine for opioid use disorder in the Emergency Department: a retrospective chart review Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers Domingos A. Treating opioid withdrawal with buprenorphine in a community hospital emergency department: an outreach program Medications for opioid use disorder, SAMHSA Treatment Improvement Protocol (TIP63): For healthcare and addiction professionals, policymakers, patients, and families. HHS Publication No. PEP20-02-01-006. National Mental Health and Substance Use Policy Laboratory Consensus statement on office-based treatment of opioid dependence using buprenorphine Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality High-dose buprenorphine induction in the Emergency Department for treatment of opioid use disorder The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: project ED Innovation. Contemporary Clinical Trials Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectivenessimplementation study (Project ED HEALTH) Managing opioid withdrawal in the emergency department with buprenorphine American College of Emergency Physicians. BUPE: buprenorphine use in the emergency department tool Guide: Screening for Drug Use in General Medical Settings Substance Abuse and Mental Health Services Administration. White paper on screening, brief intervention and referral to treatment (SBIRT) in behavioral healthcare Diagnostic and statistical manual of mental disorders (DSM-5): American Psychiatric Pub The clinical opiate withdrawal scale (COWS) Treatment of opioid and alcohol withdrawal in a cohort of emergency department patients American College of Obstetricians and Gynecologists. Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 524 Buprenorphine field initiation of ReScue treatment by emergency medical services Single dose of 24 milligrams of buprenorphine for heroin detoxification: an open-label study of five inpatients Unobserved "home" induction onto buprenorphine Office of the Secretary, Department of Health and Human Services. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. Document citation 86 FR 22439 Suboxone (buprenorphine and naloxone) sublingual film: full prescribing information Managing opioid withdrawal precipitated by buprenorphine with buprenorphine A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial Systematic review of emergency department crowding: causes, effects, and solutions The effect of emergency department crowding on clinically oriented outcomes One-year mortality after emergency department visit for nonfatal opioid poisoning: a populationbased analysis One-year mortality of patients after emergency department treatment for nonfatal opioid overdose Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study Opioid use disorder A public health strategy for the opioid crisis Substance Abuse and Mental Health Services Administration. Opioid overdose prevention toolkit. HHS Publication No. SMA18-4742. National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration American College of Emergency Physicians. Naloxone prescriptions for emergency physicians. Policy statement EMERGENCY: hospitals are violating federal law by denying required care for substance use disorders in emergency departments Consensus recommendations on the treatment of opioid use disorder in the emergency department BA, is a MD Candidate at Yale School of Medicine Emergency department-initiated buprenorphine protocols: A national evaluation The authors declare no conflict of interest. Ethan Cowan and Clara Zhang Guo conceived and designed the study methods with input from all authors. Clara Zhang Guo and Ethan Cowan reviewed all protocols, David Fiellin arbitrated discrepancies, and Clara Zhang Guo analyzed the data once aligned upon. Clara Zhang Guo and Ethan Cowan drafted the manuscript, and all authors contributed to revisions. Clara Zhang Guo takes responsibility for the paper. Clara Z. Guo BA https://orcid.org/0000-0001-6825-4291